Molecular Partners: Pioneering Targeted Radiopharmaceuticals
Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners, a Roadshow Partner of Venture Leaders Biotech, has spent two decades developing...
Read more06.05.2025 11:40 Rita Longobardi
Meet Thomas Roder, CEO of Abrinca Genomics. The biotech startup streamlines data analysis with an innovative software platform, OpenGenomeBrowser, advancing research in various microbial fields. In June, Thomas will join nine other biotech innovators on a business development and investor roadshow in Boston.
Name: Thomas Roder
Location: Bern
Nationality: Swiss
Graduated from: University of Bern
Job title: CEO
Number of employees: 3
Money raised: CHF 375,000
Can you tell us who your product or solution helps, and how?
Microbes are the foundation of life on Earth. They drive the cycles that sustain ecosystems, influence human health in ways we’re still uncovering, and power industries from agriculture to biotechnology. Yet despite their importance, microbial research is hindered by fragmented tools and inefficient workflows. Abrinca addresses this bottleneck with software that combines intuitive UX, robust data management, and a complete analytics suite. We improve research efficiency and discovery across microbial research fields including food, pathology, agriculture, and waste management.
What market are you addressing, and what is the potential of your startup in that market?
We are targeting the bioinformatics software market, projected to reach USD 15 billion by 2025. We aim to capture USD 175 million in the next five years. Unlike competitors, Abrinca’s modern platform offers flexible deployment (on-premise or cloud) and compatibility with any dataset, enabling non-bioinformaticians to conduct advanced analyses independently. This reduces workflow times from days to minutes, accelerating discovery.
Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners, a Roadshow Partner of Venture Leaders Biotech, has spent two decades developing...
Read more
Twenty years after co-founding Molecular Partners (MP), Patrick Amstutz and Michael Stumpp reflect on building a company around a novel drug class—DARPin therap...
Read more
Meet Michael Zering, Co-Founder of Apricot Therapeutics. The biotech startup aims to become the "Google Maps" of the tumor cell by combining drug perturbations,...
Read more
Meet Sasha Melkonyan, Co-Founder of Nerai. The biotech startup develops new, highly personalized gene-editing tools designed to provide lasting treatments for d...
Read more